Previous Close | 3.66 |
1-Year Change | 95.72% |
6-Months Change | -3.94% |
3-Months Change | -17.94% |
Moving Avg (50d) | 4.258 |
Moving Avg (200d) | 3.845 |
ESG Rating | - |
Exchange | NASDAQ |
Market Cap. | 2.12B |
Beta (3-Years) | 1.23 |
Revenue Growth (ttm) | -79.32% |
Net Profit Margin (ttm) | -55138.49% |
Return On Assets (ttm) | -42.32% |
EPS (ttm) | -0.35 |
PE Ratio (ttm) | -10.46 |
Dividend Yield | % |
Asset Description: | Geron Corporation |
Predicted Direction: | Buy |
Signal Strength: | Neutral |
Forecast Date: | 2024-11-20 00:00:00 |
Strong Buy | ||
Buy | ||
Neutral | ||
Sell | ||
Strong Sell |
2% | 5% | 7% | 10% | 15% | 20% |
3.959 | 3.838 | 3.757 | 3.636 | 3.434 | 3.232 |
Disclaimer - Please note that the use of AI to analyse contents may occasionally generate incorrect information.
Our cutting-edge algorithms employ macroeconomic data, fundamental and technical analysis indicators to accurately predict the optimal position for short-term trading
By harnessing these signals, we power our asset allocation tools, backtesting tool and portfolio management process, ensuring maximum returns for your investments.
Sector: | Health Care |
Industry: | Biotechnology |
Country: | United States |